BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30611565)

  • 1. Surgical resection of neuroendocrine tumor liver metastases as part of multimodal treatment strategies: A propensity score matching analysis.
    Schreckenbach T; Hübert H; Koch C; Bojunga J; Schnitzbauer AA; Bechstein WO; Holzer K
    Eur J Surg Oncol; 2019 May; 45(5):808-815. PubMed ID: 30611565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.
    Spolverato G; Bagante F; Aldrighetti L; Poultsides G; Bauer TW; Field RC; Marques HP; Weiss M; Maithel SK; Pawlik TM
    J Gastrointest Surg; 2017 Dec; 21(12):2039-2047. PubMed ID: 28744737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter?
    Xiang JX; Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    Ann Surg Oncol; 2018 Dec; 25(13):3928-3935. PubMed ID: 30218247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.
    Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Feb; 117(2):171-181. PubMed ID: 28940257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation.
    Ruzzenente A; Bagante F; Bertuzzo F; Aldrighetti L; Campagnaro T; Ercolani G; Conci S; Giuliante F; Dore A; Ferrero A; Torzilli G; Grazi GL; Ratti F; Cucchetti A; De Rose AM; Russolillo N; Cimino M; Perri P; Guglielmi A; Iacono C
    J Gastrointest Surg; 2019 Jan; 23(1):93-100. PubMed ID: 30242647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.
    Mayo SC; de Jong MC; Bloomston M; Pulitano C; Clary BM; Reddy SK; Clark Gamblin T; Celinski SA; Kooby DA; Staley CA; Stokes JB; Chu CK; Arrese D; Ferrero A; Schulick RD; Choti MA; Geschwind JF; Strub J; Bauer TW; Adams RB; Aldrighetti L; Mentha G; Capussotti L; Pawlik TM
    Ann Surg Oncol; 2011 Dec; 18(13):3657-65. PubMed ID: 21681380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Recurrence of Neuroendocrine Liver Metastasis After Curative Hepatectomy: Risk Factors, Prognosis, and Treatment.
    Zhang XF; Beal EW; Chakedis J; Lv Y; Bagante F; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Weiss M; Pawlik TM
    J Gastrointest Surg; 2017 Nov; 21(11):1821-1830. PubMed ID: 28730354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
    Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
    J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study.
    Sham JG; Ejaz A; Gage MM; Bagante F; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss MJ; Marques HP; Aldrighetti L; Pawlik TM; He J
    J Gastrointest Surg; 2019 Mar; 23(3):484-491. PubMed ID: 29980977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model.
    Spolverato G; Vitale A; Ejaz A; Kim Y; Cosgrove D; Schlacter T; Geschwind JF; Pawlik TM
    Surgery; 2015 Aug; 158(2):339-48. PubMed ID: 25999251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.
    Bertani E; Fazio N; Radice D; Zardini C; Spinoglio G; Chiappa A; Ribero D; Biffi R; Partelli S; Falconi M
    Eur J Surg Oncol; 2017 Feb; 43(2):372-379. PubMed ID: 27742480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Kostakis ID; Moris D; Schizas D; Cloyd JM; Pawlik TM
    J Gastrointest Surg; 2019 May; 23(5):1044-1054. PubMed ID: 30671800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine liver metastasis: The chance to be cured after liver surgery.
    Bagante F; Spolverato G; Merath K; Postlewait LM; Poultsides GA; Mullen MG; Bauer TW; Fields RC; Lamelas J; Marques HP; Aldrighetti L; Tran T; Maithel SK; Pawlik TM
    J Surg Oncol; 2017 May; 115(6):687-695. PubMed ID: 28146608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of surgical resections for neuroendocrine liver metastases: A project study of the Japan Neuroendocrine Tumor Society (JNETS).
    Aoki T; Kubota K; Kiritani S; Arita J; Morizane C; Masui T; Kudo A; Komoto I; Hatano E; Ito T; Osamura RY; Unno M; Uemoto S; Kokudo N;
    J Hepatobiliary Pancreat Sci; 2021 Jun; 28(6):489-497. PubMed ID: 33792204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat hepatectomy for patients with recurrent neuroendocrine liver metastasis: Comparison with first hepatectomy.
    Kiritani S; Arita J; Matsumura M; Nishioka Y; Kudo H; Ichida A; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
    Surgery; 2020 Feb; 167(2):404-409. PubMed ID: 31635827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database.
    Fairweather M; Swanson R; Wang J; Brais LK; Dutton T; Kulke MH; Clancy TE
    Ann Surg Oncol; 2017 Aug; 24(8):2319-2325. PubMed ID: 28303430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis.
    Ejaz A; Reames BN; Maithel S; Poultsides GA; Bauer TW; Fields RC; Weiss M; Marques HP; Aldrighetti L; Pawlik TM
    J Surg Oncol; 2017 Dec; 116(7):841-847. PubMed ID: 28650564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Long-Term Survival in Metastases from Neuroendocrine Neoplasms Improved by Liver Resection?
    Kraft A; Croitoru A; Moldovan C; Lupescu I; Tomescu D; Purnichescu-Purtan R; Herlea V; Popescu I; Botea F
    Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056330
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatic Resection for Metastatic Neuroendocrine Cancer in Patients with Bone Metastases.
    Croome KP; Burns JM; G Que F; Nagorney DM
    Ann Surg Oncol; 2016 Oct; 23(11):3693-3698. PubMed ID: 27188296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.
    Dogeas E; Karagkounis G; Heaphy CM; Hirose K; Pawlik TM; Wolfgang CL; Meeker A; Hruban RH; Cameron JL; Choti MA
    J Am Coll Surg; 2014 Apr; 218(4):628-35. PubMed ID: 24655849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.